Get started
Author

Shanhu Hu

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7
2019 · Shanhu Hu, Jason J. Marineau, et al. · Cancer Research · 153
Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription
2020 · Jenna K. Rimel, Zachary C. Poss, et al. · Genes & Development · 96
PDF
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7
2021 · Jason J. Marineau, Kristin B. Hamman, et al. · Journal of Medicinal Chemistry · 93
CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110
2015 · Shanhu Hu, Alexey V. Danilov, et al. · Cancer Research · 54
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer
2016 · Masanori Kawakami, Lisa Maria Mustachio, et al. · JNCI Journal of the National Cancer Institute · 50
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2
2016 · Alexey V. Danilov, Shanhu Hu, et al. · Molecular Cancer Therapeutics · 50
Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer
2017 · Lisa Maria Mustachio, Yun Lu, et al. · Molecular Cancer Research · 45
Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
2015 · Shanhu Hu, Yun Lu, et al. · Molecular Cancer Therapeutics · 24
Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo
2019 · Shanhu Hu, Jason Marineau, et al. · Cancer Research · 14
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
2025 · Taylor Jones, Junjie Feng, et al. · Science Advances · 13
Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications
2019 · Liv H Johannessen, Shanhu Hu, et al. · Molecular Cancer Therapeutics · 10
Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activityin vivo
2019 · Shanhu Hu, Jason Marineau, et al. · Molecular and Cellular Biology / Genetics · 6
Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia
2017 · Graeme Hodgson, Liv Johannessen, et al. · Blood · 5
Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
2020 · Liv Johannessen, Nan Ke, et al. · Journal of Clinical Oncology · 3
Abstract 1143: Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
2017 · Michael Bradley, Jason Marineau, et al. · Cancer Research · 3
Abstract 1151: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors
2017 · Shanhu Hu, Nan Ke, et al. · Cancer Research · 3
Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
2017 · Kristin Hamman, Michael Bradley, et al. · The FASEB Journal · 2
三亚城区pm 2.5 中水溶性离子特征与来源分析
2021 · 胡珊瑚, HU Shanhu, et al. · 1
Abstract B171: PK/PD modeling of the first-in-class, potent and selective covalent CDK7 inhibitor, SY-1365, provides mechanistic basis for intermittent dosing regimens in preclinical efficacy models of hematologic and solid tumors
2018 · Nigel J. Waters, Shanhu Hu, et al. · Molecular Cancer Therapeutics · 1
Abstract 4820: Selective CDK7 inhibitors suppress super enhancer-genes, induce massive apoptosis in acute myeloid leukemia and demonstrate durable in vivo efficacy
2016 · Shanhu Hu, Nan Ke, et al. · Cancer Research · 1
Targeting Transcriptional Dependency in Acute Myeloid Leukemia (AML) with a Covalent Inhibitor of Transcriptional Kinase CDK7
2015 · Yixuan Ren, Victoria Brown, et al. · Blood · 1
Abstract 942: Novel CDK2/9 inhibitor has antineoplastic activity in lung cancer by inducing anaphase catastrophe
2015 · Masanori Kawakami, Lisa Maria Mustachio, et al. · Cancer Research · 1
Supplemental Fig. S5 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
2023 · Shanhu Hu, Yun Lu, et al.
Supplemental Fig. S3 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
2023 · Shanhu Hu, Yun Lu, et al.
Supplemental Table S1 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
2023 · Shanhu Hu, Yun Lu, et al.
Works count: 61
Citation count: 629
H-index: 10
I10-index: 11
Year
Topic
Type